Modification of collagenous materials and medical treatment, diagnosis and monitoring of fibrotic conditions

ABSTRACT

The present invention relates to the gene PLOD2 which codes for telopeptide lysyl hydroxylase (TLH). This enzyme converts telopeptidyl Lys into telopeptidyl Hyl, that can subsequently be converted into hydroxyallysine cross-links. Collagen with hydroxyallysine cross-links shows a higher resistance to degradation by proteinases than collagen with cross-links derived from allysine. In one aspect, the invention provides methods and compositions to prepare collagenous materials with varying biodegradation rates by varying the ratio of hydroxyallysine cross-links over allysine cross-links. In another aspect, the invention provides methods and compositions to lower the ratio of hydroxyallysine cross-links over allysine cross-links in fibrotic processes, in order to obtain a collagenous network that is more easy to degrade. Furthermore, the invention provides methods to diagnose and/or monitor fibrotic processes by measuring mRNA levels of PLOD2, by measuring protein levels of the translated mRNA, and/or by measuring enzymatic activity levels of TLH. The invention also provides the description of a high through-put system facilitating the screening of antagonists of telopeptide lysyl hydroxylase.

This application is a divisional application of U.S. Ser. No.10/184,372, filed Jun. 28, 2002, which is a continuation-in-part of U.S.Ser. No. 09/450,209, filed Nov. 29, 1999.

FIELD OF THE INVENTION

This invention is in the general field of modifying collagenousmaterials in order to increase or decrease their stability towardsenzymatic degradation (in particular by proteinases). Furthermore, theinvention is in the field of medical treatment of fibrotic conditions,and in the fields of diagnosis and/or monitoring of fibrotic processes.Furthermore, the invention is in the field of screening tests forsubstances that are potentially useful in the treatment of fibroticconditions.

BACKGROUND OF THE INVENTION

Fibrillar collagens (e.g. collagen type I, II, III, V and XI) consist ofa triple helical domain, flanked by telopeptides at both theaminoterminal and carboxyterminal end of the molecule (N-telopeptide andC-telopeptide, respectively). Biosynthesis of collagen is a multistepprocess, resulting in modifications of both the triple helix and thetelopeptides. One of the steps in the biosynthesis of collagen ishydroxylation of certain lysine residues in the triple helix andtelopeptides by the enzyme lysyl hydroxylase (EC 1.14.11.4).

Extracellular collagen molecules aggregate spontaneously intomicrofibrils. Further stabilization of the molecules occurs by means ofcross-links. Cross-linking is initiated by conversion of specific lysine(Lys) or hydroxylysine (Hyl) residues of the telopeptides into thealdehydes allysine and hydroxyallysine, respectively, by the enzymelysyl oxidase (EC 1.4.3.13) [H. M. Kagan, 1994, Path. Res. Pract., 190:910-919]. The aldehydes subsequently react with Lys or Hyl residues inthe triple helix to give characteristic di-functional cross-links. Thesecross-links eventually mature into tri- or tetra-functional cross-links[D. R. Eyre, 1987, Meth. Enzymol., 144: 115-139; A. J. Bailey et al.,1998, Mech. Ageing Developm, 106: 1-56].

Two related routes for the formation of cross-links have been described,one based on allysine from the telopeptides, the other based onhydroxyallysine from the telopeptides. Each route results in chemicallydistinct cross-links. Examples of the hydroxyallysine cross-links arehydroxylysylpyridinoline (HP) and lysylpyridinoline (LP); the precursorsof these cross-links are di-functional cross-links known in theirreduced form as dihydroxylysinonorleucine (DHLNL) andhydroxylysinonorleucine (HLNL), respectively.

It is well known that the stability of collagen molecules inenvironments containing proteinasesdepends, amongst others, on the levelof cross-linking. The stability of collagen molecules againstproteinases can be enhanced by increasing the amount of cross-links.Cross-links can be enzymatically mediated cross-links andnon-enzymatically mediated cross-links. The enzymatically mediatedcross-links are generated by lysyl oxidase. Introduction of cross-linksin a non-enzymatic way can be achieved by treating collagen with avariety of chemicals, such as aldehydes, epoxides, isocyanates, acylazides, carbodiimides, reducing sugars (the so-called Maillardreaction), or by a variety of physical methods, such as irradition (e.g.short-wave UV irradiation) or dehydrothermal treatments. There is anextensive amount of literature and patents dealing with controlling thebiodegradation time of collagen by means of enhancing collagencross-linking by lysyl oxidase, chemicals or physical methods.Controlling the degradation time of collagenous materials is highlyimportant, especially in the field of drug release and tissueengineering. The starting point to engineer a tissue is the design of ascaffold and a consideration of the kind of cells to be seeded into thescaffold. Scaffolds can also be used in various wound healingsituations. Biodegradation of scaffolds is required to prevent longtermphysical hindrance of the implant. The rate of degradation is dependenton the application and has to be in concert with tissue formation.Collagen is often used as a basis for the manufacturing of scaffolds.For a number of applications, non-crosslinked collagen cannot be usedbecause of its susceptibility to decomposition by metalloproteinasesbefore it can be remodelled into a resistant replacement. In such cases,a collagen scaffold is needed showing higher resistancies towardproteinases. Therefore, various methods have been developed to controlthe speed of degradation of collagen, such as the above mentionedchemical and physical methods.

A disadvantage of chemical and physical methods is that the position ofthe cross-links within the molecule cannot be controlled: cross-linksare generated throughout the molecule. In addition, said cross-links canbe intramolecular or intermolecular. Another disadvantage is that mostchemical and physical methods partially denature the collagen molecules:denatured collagen is highly susceptible to proteolytic degradation.Other disadvantages are that certain cross-links show some toxicity,have immunogenic properties, adversity affect biomechanical properties,adversity affect cell/matrix interactions, or that the treatmentenhances unwanted side-effects, such as calcification of the matrix.

These problems can be overcome by using lysyl oxidase: the formedaldehydes react with amino acids located at very specific positionswithin the triple helix. Furthermore, because the cross-links normallyoccur in vivo, the cross-links do not show toxicity or immunogenicity,and the treatment with lysyl oxidase does not result in a denaturationof collagen molecules.

In some cases, the durability of collagen molecules cross-linked bymeans of lysyl oxidase in proteolytic environtnmes is not high enough,resulting in biodegradation times that are too short. In other cases,collagen cross-linked by lysyl oxidase show biodegradation times thatare too long. The latter is for example the case in fibrosis. Infibrotic conditions an unwanted accumulation is seen of collagenmolecules that is difficult to degrade by proteinases.

SUMMARY OF THE INVENTION

A need exists for tools controlling the biodegradation time ofcollagenous materials based on the formation of naturally occurringcross-links. Here we show that collagen cross-linked by hydroxyallysinecross-links is more resistant toward proteolytic enzymes and moredifficult to degrade than collagen cross-linked by allysine. Bothcross-links occur in vivo and are generated by lysyl oxidase. Ourapproach is unique in that it controls the biodegradation time ofcollagens by controlling the lysyl hydroxylation level of thetelopeptides. This is achieved by controlling the levels of telopeptidelysyl hydroxylase, the enzyme that hydroxylates the lysine residueslocated in the telopeptides.

The present invention also relates to the observation that the amount ofhydroxyallysine cross-links is enhanced in fibrotic tissues, explainingin part the irreversibility of collagen accumulation in fibrosis.

Here we also show that the gene PLOD2 encodes a telopeptide lysylhydroxylase, making it possible to regulate the lysyl hydroxylationlevel of the telopeptides. Previously, it was not known whether theenzyme encoded by PLOD2 hydroxylates the Lys in the telopeptides or theLys in the triple helix of the collagen.

The invention has a broad applicability: it can be used for thepreparation of collagenous materials used in tissue engineering or drugdelivery but also in the field of medical treatments aimed at inhibitingfibrotic processes. In fibrotic tissues, a switch is seen in thetelopeptide-lysyl-crosslink pathway toward thetelopeptide-hydroxylysyl-crosslink pathway. Inhibition of the synthesis(transcription, translation) of the enzyme encoded by PLOD2 and/orinhibition of the enzymatic activity of the PLOD2-encoded proteinresults in a collagen network that is predominantly cross-linked bymeans of allysine cross-links, a network that is more easy to degrade byproteinases. The subject invention also concerns new materials andmethods for the detection of fibrotic processes based on the novelfinding that the gene PLOD2 encodes telopeptide lysyl hydroxylase andthat this enzyme plays a key role in fibrosis.

The present invention provides methods for the preparation ofcollagenous materials exhibiting variable degradation times inenvironments containing proteolytic enzymes, based on modifying thehydroxylysine levels in the telopeptides.

The present invention provides a new method for selectively inhibitingthe formation of hydroxyallysine cross-links, but not allysine-derivedcross-links in wound healing and in other processes in which fibrosisoccurs, thus increasing the proteolytic degradation rate of theassembled collagen network. The selectivity of the method is such thatbiosynthesis of allysine cross-links will not be compromised, thusresulting in collagen with favourable mechanical properties overnon-cross-linked collagen. This specificity can be achieved byadministration of an effective amount of a composition that selectivelyinhibits the activity or production of telopeptide lysyl hydroxylase butnot lysyl oxidase.

The subject invention furthermore concerns methods for estimating ordetermining the amount of mRNA copies transcribed from the PLOD2 gene asa means to monitor the onset and/or the progression offibrosis/scarring. The invention further provides methods for measuringthe amount of PLOD2-encoded enzyme in a sample by means of antibodiesand/or aptamers or other means, and methods for determining telopeptidelysyl hydroxylase activity levels in a sample using one or morehydroxylatable sequences. Said methods are tools to diagnose or monitorfibrotic processes.

Additionally, the invention provides methods for measuring telopeptidelysyl hydroxylase activity in a test system designed to screen compoundsexhibiting inhibitory properties towards the activity of the enzyme orantagonist properties with respect to the transcription of the PLOD2gene or the translation of the respective RNA template.

Further objects and advantages of the invention with respect tocompositions capable of suppressing or repressing the synthesis(transcription and/or translation) of telopeptide lysyl hydroxylaseand/or compounds capable of inhibiting the activity of said enzyme willbe clear to one skilled in the art upon consideration of the followingdetailed description.

Examples demonstrate (1) that collagen cross-linked by allysine iseasier to degrade by proteinases than collagen cross-linked byhydroxyallysine, (2) various mutations of the PLOD2 gene in Brucksyndrome, showing that PLOD2 is a telopeptide lysyl hydroxylase, (3)that increased PLOD2 expression levels result in increasedhydroxyallysine cross-link levels, (4) methods to measure mRNA levels ofPLOD2, (5) that expression of PLOD2 is highly increased inmyofibroblasts, cells that mediate fibrosis, (6) formats of a highthrough-put assay designed to screen compounds exhibiting inhibitoryproperties towards telopeptide lysyl hydroxylase, (7) methods to preparecollagenous materials with varying degradation rates, (8) methods toincrease telopeptide lysyl hydroxylase levels in cells in order toobtain collagen with high lysyl hydroxylation levels in thetelopeptides, (9) methods to inhibit telopeptide lysyl hydroxylase inorder to obtain collagen with low lysyl hydroxylation levels in thetelopeptides.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the graphs depicting (A) the level of collagen degradationproducts (Hyp=hydroxyproline) as well as (B) the hydroxyproline toproline (Hyp:Pro) ratio in Bruck syndrome urine, compared to urine fromhealthy subjects and urine from osteogenesis imperfecta (01) patients.The data indicate that the degradation of bone collagen in Brucksyndrome, which is characterized by the almost complete absence ofhydroxyallysine cross-links, is significantly elevated.

FIG. 2 is a pedigree of a Bruck syndrome family (family DR and familyPM) showing the genotypes in the region of homozygosity on chromosome 3reference interval D03 S 1764-D03S1594 (164.6-168.3 cM) where the genePLOD2 is located. Black symbols denote affected individuals and stripedsymbols denote carriers of the disease. The haplotypes co-segregatingwith the disease are indicated with a black box. Both pedigrees provideevidence that PLOD2 is the candidate gene for telopeptide lysylhydroxylase.

FIG. 3 is a graph showing the missense mutation found in Bruck syndromefamily PM, resulting in a Gly→Val mutation in the sequence GGYENVPT (SEQID NO: 1) (the mutated residue is underligned).

FIG. 4 is a graph showing the missense mutation found in Bruck syndromefamily DR, resulting in a Thr→Ile mutation in the sequence GGYENVPT (SEQID NO: 1) (the mutated residue is underligned). Both FIG. 3 and 4provide direct evidence that PLOD2 encodes telopeptide lysylhydroxylase.

FIG. 5 is a graph showing the mRNA levels of PLOD2B (normalized againstL 2-microglobulin mRNA levels) in cultured human fibroblasts andcultured human myofibroblasts as determined by multiplex real-time PCR.The data show that PLOD2B is highly expressed in myofibroblasts, cellsthat play a key role in fibrotic processes.

FIG. 6 is a graph showing the construct pDHPL2b.5 derived from thepMOSBlue vector used for the expression of recombinant PLOD2B inmammalian cells.

FIG. 7 is a graph showing the expression of PLOD2B during osteogenicdifferentiation of human bone marrow cells. The amount of mRNA derivedfrom PLOD2B is essentially the same in the various differentiationphases.

FIG. 8 is a graph showing that the expression of PLOD2B is inhibited infibroblasts and myofibroblasts by adding minoxidil to the culturemedium.

FIG. 9 is a graph showing that the expression of PLOD2B is increased infibroblasts by adding TGF-R to the culture medium.

DETAILED DESCRIPTION OF THE INVENTION

The invention provides a method for obtaining a collagenous matrix whichcomprises cross-linked collagen molecules wherein the resistance of saidcollagenous matrix against proteolytic degradation is controlled bycontrolling the ratio of hydroxyallysine cross-links to allysinecross-links in the collagenous matrix. The ratio of hydroxyallysinecross-links to allysine cross-links in the collagenous matrix may becontrolled by controlling the lysyl hydroxylation level of the collagentelopeptides. The lysyl hydroxylation level of the collagen telopeptidesmay be controlled by controlling the level of telopeptide lysylhydroxylase activity. The level of telopeptide lysyl hydroxylaseactivity may be controlled by controlling the expression of a PLOD2 geneor by controlling the telopeptide lysyl hydroxylase activity of a PLOD2expression product. Preferably, the level of telopeptide lysylhydroxylase activity is controlled without simultaneously affectinghelical lysyl hydroxylase activity, although a simultaneous increase ordecrease of helical lysyl hydroxylase activity may be accepted. Morepreferably, the level of telopeptide lysyl hydroxylase activity iscontrolled in such a way that lysyl oxidase activity is not affected.Thereby, the invention allows to achieve a modified ratio ofhydroxyallysine cross-links to allysine cross-links in the collagenousmatrix without significantly affecting the overall degree ofcross-linking.

The invention comprises methods which are carried out in vitro, inparticular methods for producing a collagenous matrix with a desirableresistance against proteolytic degradation or breakdown, i.e. adesirable biodegradation time, in particular a desirable high or lowstability against proteolytic degradation. Such in vitro methods mayinvolve the use of living cells for producing collagen, but may also becompletely cell-free. The invention further comprises methods carriedout in vivo, i.e. in living mammals, in particular in human beings,wherein a major application is in a treatment of fibrotic conditions.

Furthermore, the invention provides a method for diagnosing and/ormonitoring the occurrence or state of a fibrotic process in a mammalcomprising taking a sample (in particular a tissue sample) from saidmammal, analyzing said sample to determine the expression level of aPLOD2 gene and comparing said expression level with a standard.

The invention also provides an assay (in particular a high-troughputassay) for screening compounds or compositions to determine their effecton telopeptide lysyl hydroxylase activity comprising contacting underenzymatically functional conditions a compound or composition to betested with a PLOD2-encoded telopeptide lysyl hydroxylase enzyme and asuitable substrate for this enzyme, and determining the level of lysylhydroxylation of the substrate compared to the level of lysylhydroxylation of the substrate in the absence of the compound orcomposition to be tested. Such assay preferably further comprisesseparating, after said contacting of the compound or composition to betested with a PLOD2-encoded telopeptide lysyl hydroxylase enzyme andsuitable substrate for it, the substrate from the reaction mixture,reacting the substrate successively with an oxidizing agent, such asperiodate, which is capable of oxidizing the hydroxyl group of Hyl to analdehyde moiety, and a hydrazide dye, and measuring the fluorescencefrom the substrate.

Further, the invention provides an assay for screening compounds orcompositions to determine their effect on telopeptide lysyl hydroxylaseexpression comprising growing cells expressing a PLOD2-encodedtelopeptide lysyl hydroxylase enzyme in the presence of a compound orcomposition to be tested and determining the level of PLOD2 expressioncompared to the level of PLOD2 expression in the absence of the compoundor composition to be tested.

Definitions

Telopeptide lysyl hydroxylase refers to an enzyme that is capable ofconverting lysine residues of collagen telopeptides into hydroxylysine.As opposed to helical lysyl hydroxylase, telopeptide lysyl hydroxylasehas a higher affinity for Lys located in the telopeptides than Lyslocated in the triple helical part of the collagen molecule.

In this invention, the term telopeptide lysyl hydroxylase refers to thebiologically active enzyme encoded by the nucleic acid sequence of thePLOD2 gene, or a nucleic acid sequence homologous to it. Said enzyme isderived from the complete mRNA sequence of PLOD2, a splice variantthereof, or a fragment of the PLOD2 nucleic acid sequence (but stillencoding a polypeptide displaying biological activity in the sense thatit hydroxylates lysine residues in the telopeptides). The invention alsoencompasses PLOD2 variants, i.e. differing in nucleotide sequence oreven in amino acid sequence of the encoded polypeptide, but stillencoding a polypeptide displaying activity in the hydroxylation oflysine residues in the telopeptides. Several PLOD2 variants are known inthe art. A preferred PLOD2 variant is one having at least 90% amino acidsequence identity to the PLOD2 amino acid sequence. As a result of thedegeneracy of the genetic code, a multitude of polynucleotide sequencesencoding telopeptide lysyl hydroxylase, some bearing minimal homology tothe polynucleotide of PLOD2, may be produced. Thus, the inventioncontemplates each and every possible variation of polynucleotidesequences that could be made by selecting combinations based on possiblecodon choices.

Some examples of known PLOD2 sequences can be found in M. Valtavaara etal. (1997, J. Biol. Chem., 272 (11): 6831-6834), H. N. Yeowell & L. C.Walker (1999, Matrix Biology, 18: 179-187), H. Ruotsalainen et al.(1999, Matrix Biology, 18: 325-329), and H. Ruotsalainen et al. (2001,Matrix Biology, 20: 137-146). Said publication by Yeowell & Walkerdescribed the presence of two splice variants of PLOD2. In this patentapplication, PLOD2A refers to the short form, whereas PLOD2B refers tothe form of PLOD2 containing exon 13A (located between exon 13 and exon14).

The words “inhibits the activity or production of telopeptide lysylhydroxylase” are used herein in a broad sense, in that they not onlycover the actual inhibition of the enzyme as such, but also cover aninhibition of the transcription of the telopeptide lysyl hydroxylasegene, inhibition of the translation of mRNA derived from the telopeptidelysyl hydroxylase gene, and treatment with (a recombinant gene codingfor) a mutated telopeptide lysyl hydroxylase or a fragment thereof thatshows no activity towards telopeptides but that is competitive toendogenous telopeptide lysyl hydroxylase with respect to its naturalsubstrate (collagen telopeptides).

The term “antagonist” as it is used herein, refers to a molecule whichdecreases the amount or duration of the effect of the biologicalactivity of telopeptide lysyl hydroxylase. Antagonists may includeproteins, nucleic acids, carbohydrates, antibodies, aptamers, or anyother molecules which decrease the effect of telopeptide lysylhydroxylase.

Fibrosis is a disorder or undesirable physical condition characterizedby excessive deposition of collagen, resulting in scarring of theaffected tissue(s).

Collagen Cross-Linked by Allysine Shows a Different Molecular Packing inFibrils and is More Easily Degraded Compared to Collagen Cross-Linked byHydroxyallysine

The bone collagen in Bruck syndrome lacks the hydroxyallysinecross-links of normal bone; the cross-links are replaced by allysinecross-links [R. A. Bank et al., 1999, Proc. Natl. Acad. Sci. USA, 96:1054-1058]. To corroborate whether allysine cross-linked collagenmolecules are more prone to degradation by proteolytic enzymes, bothdemineralized Bruck syndrome bone (containing allysine cross-links) anddemineralized control bone (containing hydroxyallysine cross-links) weretreated with pepsin dissolved in 0.5 M acetic acid. Demineralized Brucksyndrome bone treated with pepsin resulted in a release of 65% of thecollagen molecules (compared to 5% of normal bone). Treatment ofdemineralized Bruck syndrome bone as well as demineralized control bonein 0.5 M acetic resulted in the solubilization of 7% and 1% of thecollagen molecules, respectively, indicating that the value of 65%released collagen is mainly due to the action of pepsin.

Additional evidence that allysine cross-linked collagen molecules aremore prone to degradation by proteolytic enzymes was obtained bymeasuring hydroxyproline (Hyp) levels in urine of Bruck syndromepatients. We analyzed the urine of patients clinically diagnosed withBruck syndrome (most patients have been described in the literature).The data presented in one of the examples show that the urinary level ofhydroxyproline (μmol Hyp/mmol creatinine) in Bruck syndrome is higherthan age-related controls or age-related osteogenesis imperfectapatients (FIG. 1A; P<0.001), showing that there is an increase of Brucksyndrome bone.

Interestingly, pepsinized collagen from Bruck syndrome bone (containingpredominantly allysine cross-links) shows on SDS-electrophoresis two8-bands ((31,1 and 81,2 in a 1:2 ratio) whereas pepsinized collagen fromnormal bone (containing predominantly hydroxyallysine cross-links) showson SDS-electrophoresis three 8-bands ((31,1, 81,2 and 82,2 in a 1:1:1ratio). The 8-bands are two a-chains connected to one another by meansof a di-functional cross-link. Cross-linking of collagen involves a fewspecific amino acids only. For steric and chemical reasons only theseamino acids are able to react with each other when collagen moleculesare correctly aligned. Consequently, variations in the packingarrangement must have an impact on the amount and nature of cross-links,or vice versa. In either case, cross-link patterns can be used as amarker to probe the alignment of intrafibrillar collagen molecules. Itoccurs to us that the difference in 8-band patterns after pepsinizationis the result of a different packing of the collagen molecules. J.Brinckmann et al. [1996, J. Invest. Dermatol., 107: 589-592] alsodisclosed that collagen molecules cross-linked by allysine show apacking arrangement within fibrils that is different from the packing ofcollagen molecules containing hydroxyallysine cross-links. We postulatethat this difference in packing is causally involved in the observedincreased degradation rate of allysine cross-linked collagen.

One of the examples describes a method for the preparation ofcollagenous compositions showing various ratios of hydroxyallysine overallysine cross-link ratios, thus showing various degradation ratestowards proteinases.

In conclusion, collagen molecules cross-linked by allysine are both invitro and in vivo more prone to proteolytic degradation. This explainsthe high excretion of collagen degradation products in urine of Brucksyndrome patients and consequently the osteoporotic status of thepatients. Vice versa, one can state that collagen cross-linked byhydroxyallysine is more resistant towards proteinases. This observationprovides new tools for the preparation of collagenous materialsexhibiting various degradation times in environments containing one ormore proteinases: the residence time of collagenous materials can beincreased by increasing the hydroxylysine level in the telopeptides. Itis remarkable, that the effects of the type of enzymatically mediatedcross-links on the susceptibility of collagen to proteolytic enzymes hasnever been investigated and never been taken into consideration as atool for increasing or decreasing the biodegradation time of collagenousmatrices, despite the fact that it is known for a long time that thepresence of hydroxyallysine-derived cross-links is indicative forirreversible collagen deposition (such as is seen in fibrosis, seebelow). A possible explanation fir this ignorance is, that it was until)now not known how the conversion of lysine into hydroxylysine oftelopeptides could be controlled. The conversion is mediated by theenzyme telopeptide lysyl hydroxylase. In order to control the conversionof lysine into hydroxylysine of the telopeptides, one needs to know theidentity of said enzyme and its working mechanism. We will show in thefollowing paragraph (6.2) that the gene PLOD2 encodes for telopeptidelysyl hydroxylase.

Sequencing of PLOD2 in Bruck Syndrome Patients Revealed Mutations,Providing Direct Evidence that the Gene PLOD2 Encodes for TelopeptideLysyl Hydroxylase

Hydroxylation of Lys in the triple helix of collagen occurs exclusivelyon Lys present in the sequence GIy-X-Lys-Gly; a Lys in the X position isnot hydroxylated. The hydroxylated Lys in the telopeptides is embeddedin an entirely different amino acid sequence. In view thereof, theexistence of two classes of enzymes has been postulated: a class ofenzymes that converts the Lys in the triple helical sequence intohydroxylysine (Hyl) (helical lysyl hydroxylase) and a class of enzymesthat is responsible for the conversion of Lys in the telopeptides intoHyl (telopeptide lysyl hydroxylase).

The most direct evidence that a class of telopeptide lysyl hydroxylasesmust exist has been derived from cross-link studies in Ehlers-Danlostype VI syndrome (EDS-VI) and Bruck syndrome. EDS-VI is a disease thatis biochemically characterized by a hydroxylysine deficiency of thetriple helix of collagen. EDS-VI patients show a normal level ofpyridinolines in tissues (e.g. in collagen type I from bone) and anormal excretion level of pyridinolines in urine [B. Steinmann et al.,1995, Am. J. Hum. Genet., 57: 1505-1508; ACil Y, et al., 1995, J. Am.Acad. Dermatol., 33: 522-524]. Pyridinolines are cross-links derivedfrom the hydroxyallysine route. Thus, in EDS-VI, despite the deficiencyof Hyl in the triple helix, a normal amount of Hyl is present in thetelopeptides. From this it follows, that the mutated gene in EDS-VI iscoding for a helical lysyl hydroxylase. In Bruck syndrome, the oppositeis seen: in bone, normal Hyl levels of the triple helix of collagen isseen, whereas hydroxyallysine-derived cross-links are virtually absent[R. A. Bank et al., 1999, Proc. Natl. Acad. Sci. USA, 96:1054-1058].Thus, in Bruck syndrome, despite normal levels of triple helical Hyl, adeficiency of Hyl in the telopeptides is observed. By definition, themutated gene in Bruck syndrome is a telopeptide lysyl hydroxylase or acofactor that is involved in TLH activity or a transcription factor thatis involved in the expression/synthesis of the enzyme.

So far, three lysyl hydroxylase genes have been identified: PLOD1, PLOD2and PLOD3. The abbreviation PLOD is derived from procollagen-lysine,2-oxoglutarate 5-dioxygenase (which is the systematic name of lysylhydroxylase), whereas the 1, 2 and 3 indicates the sequence ofdiscovery. Expression of the three PLOD genes shows a tissue-specificdistribution [M. Valtavaara et al., 1997, J. Biol. Chem., 272:6831-6834; M. Valtavaara et al., 1998, J. Biol. Chem., 273: 12881-12886;K. Passoja et al., 1998, Proc. Natl. Acad. Sci. USA, 95: 10482-10486; H.Ruotsalainen et al., 1999, Matrix Biol., 18: 325-329]. PLOD2 also showsa tissue-specific splice variant [H. N. Yeowell & L. C. Walker, 1999,Matrix Biol., 18: 179-187]. Furthermore, there is some evidence at theDNA level that tissue-specific forms of PLOD] exist [H. N. Yeowell etal., 1994, J. Invest. Dermatol., 102: 382-384]. PLODI-3 have beenexpressed in a Baculovirus expression system; the proteins encoded bythe cDNA exhibit activity towards the synthetic peptide containing thehelical sequence IKGIKGIKG or ARGIKGIRGFSG. Although the specificity ofthe expressed gene products of PLODI-3 towards the different collagentypes has so far not been investigated, the relatively low amino acidsequence homology between the different lysyl hydroxylases (around50-60%) suggests differences in the substrate properties orfunctionality of said enzymes.

PLOD1 is the gene that is mutated in Ehlers-Danlos type VI syndrome(EDS-VI) [J. Brinckmann et al., 1998, Arch. Dermatol. Res., 290:181-186; H. N. Yeowell & L. C. Walker, 2000, Molec. Genet. Metab., 71:212-224], a disease that is biochemically characterized by ahydroxylysine deficiency of the triple helix of collagen. In EDS-VI, anormal hydroxylation of the telopeptides is seen. Thus, the PLODI geneencodes most likely for a triple helical lysyl hydroxylase.

So far, no disease has been associated with PLOD2 or PLOD3. In apublication by R. A. Bank et al. [1999, Proc. Natl. Acad. Sci. USA, 96:1054-1058], a Bruck syndrome family of Kurdish origin is shown where thedefect (namely the absence of Hyl in the telopeptides of bone collagen)links to chromosome 17p12. This excludes PLOD2 and PLOD3 as candidategenes, as they are located on chromosome 3 and 7, respectively. Thesubstrate specificity of the lysyl hydroxylase encoded by PLOD2 andPLOD3 is not known; the only substrate studies performed on both enzymesare incubations with a peptide displaying the helical sequence IKGIKGIKGor ARGIKGIRGFSG. Both enzymes were capable of hydroxylating thesehelical sequences [M. Valtavaara et al., 1997, J. Biol. Chem., 272:6831-6834; M. Valtavaara et al., 1998, J. Biol. Chem., 273: 12881-12886;K. Passoja et al., 1998, Proc. Natl. Acad. Sci. USA, 95: 10482-10486].From these data one would conclude that PLOD2 and PLOD3 encode forhelical lysyl hydroxylases. In addition, PLOD2 is expressed in skin [H.N. Yeowell & L. C. Walker, 1999, Matrix Biology, 18: 179-187; C. Wang etal., 2000, DNA and Cell Biology, 19: 71-77], a tissue wherehydroxyallysine cross-links are present in extremely low levels. Thiswould again suggest, that PLOD2 encodes for a helical lysyl hydroxylase.

A study on osteoblasts and/or precursors thereof provided data that theelevation of Lys hydroxylation in the telopeptides of type I collagen atday 16 (mineralization stage) coincide with a higher expression of PLOD2mRNA [K. Uzawa et al., 1999, J. Bone Miner. Res., 14: 1272-1280]. Basedon these data, the authors hypothesized that the PLOD2 gene might beinvolved in telopeptide lysyl hydroxylation. However, the data are notconvincing: for the formation of pyridinoline cross-links a few days arerequired, and in this period PLOD2 expression is low, as is shown bysaid authors (their FIG. 3, second row, mRNA levels at the earlydifferentiation stage=day 8). Their conclusion has thereforesubsequently been ignored by other workers in the field. In fact, wehave measured PLOD2 levels in osteoblasts and/or precursors thereof aswell and did not find an increase of PLOD2 levels during osteoblasticdifferentiation, including the mineralization stage (FIG. 7). This wasdone with real-time PCR technology, which is much more reliable than theNorthern blot technology used by Uzawa et al.

We have now investigated another consanguineous Bruck syndrome family(family PM) of Kurdish origin with 2 affected children but withouthealthy children (one of the children is case 8 of E. J.Breslau-Siderius et al., 1998, J. Pediatr. Orthop. B, 7: 35-38). In thispedigree an absence of linkage was found with our published markers ofchromosome 17: haplotype analysis revealed that the affected childreninherited different maternal chromosomes. The lysyl hydroxylase encodedby PLOD2 is, according to Gene Map 98, located on chromosome 3 betweenthe interval D3S1550 and D3S1306 (sex average 159.8 cM and 164.25 cM,respectively). Haplotype analysis was carried out of the parents and thetwo affected with the DNA markers D03S1764 (sex average 152.62 cM),D03S1512 (sex average 158.38 cM), D03S1744 (161.04 cM), D03S3618 (163.18cM and D03S1594 (168.94 cM). The affected individuals were homozygousfor D03S1512, D03S1744, D03S3618 and D03S1594 and haplotype analysisshowed that the affected children inherited two identical copies of thatchromosomal region (i.e. homozygous by descent) (FIG. 2B). Thus, a goodlinkage was found in this Bruck syndrome family and the chromosomalregion where PLOD2 is located. In conclusion, this Bruck syndrome familysurprisingly provides genetic evidence that the lysyl hydroxylaseencoded by PLOD2 is telopeptide lysyl hydroxylase. A second Brucksyndrome family (family DR) also shows linkage to chromosome 3 (FIG.2A).

The primary structure of PLOD2 published in literature is primarilybased on a cDNA sequence, meaning that the intron/exon boundaries arenot known. PLOD1 and PLOD2 have 19 exons; intron/exon boundaries ofthese two genes are identical. As PLOD2 is highly homologous with PLOD1and PLOD3, it is also expected that the exon/intron boundaries coincidewith that of PLOD1 and PLOD3. This was confirmed by analyzing thesequence of Homo sapiens chromosome 3 clones RP11-758114 (GenBank codeAC053539) and RP11-274H2 (GenBank code AC018369). In addition, an extraexon (not seen in PLOD1 and PLOD3), designated as exon 13A, is anintegral part of PLOD2. To provide direct evidence that PLOD2 encodesfor a telopeptide lysyl hydroxylase, exon 1 to exon 19 as well as exon13A were individually amplified by means of a polymerase chain reaction(PCR) with primers located in the introns flanked at the 5′ and 3′ sideof each exon using TaKaRa La Taq polymerase. This was done with genomicDNA (purified by means of standard methods) from Bruck syndromepatients, from the unaffected parents, and from commercially availablegenomic DNA obtained from a healthy control population (RocheDiagnostics, Cat. No. 1691112). Amplified exons of the expected size (asdetermined on 1% agarose gels) were separated from the free dNTP's andthe polymerase by means of the Qiagen PCR purification kit. The purifiedexons were stained with fluorescent labeled dideoxy nucleotides(ddNTP's) in a cycle sequence PCR using the ABI PRISM™ BigDyeTermination Cycle Sequencing Ready Reaction Kit and analyzed by means ofcapillary electrophoresis using the ABI PRISM™ 310 apparatus. Fordetails of the used primers and PCR conditions for the amplification ofthe individual exons see one of the Examples. Sequence analysis of twoBruck syndrome patients of family PM revealed a nucleotide missensemutation resulting in a Gly6→Val mutation in the sequence GGYENVPT (SEQID NO: 1). This mutation was found on both alleles. Both parents werecarrier for this missense mutation (see FIG. 3). In one Bruck syndromepatient of family DR a nucleotide missense mutation resulting in aThr→Ile mutation in the sequence GGYENVPT (SEQ ID NO: 1). The patientwas homozygous for the mutation while both parents and a healthy sisterwere heterozygous for this mutation (see FIG. 4). The two differentpoint mutations found in family PM and DR were situated in a sequencethat shows 100% amino acid homology between the different PLOD2 andbetween different species. This suggests an important role of thisregion in the function of lysyl hydroxylases in general and that ofPLOD2 in particular.

In conclusion, we have shown in this paragraph, much to our surprise inview of the evidence that pointed in another direction, that PLOD2encodes for a telopeptidyl lysyl hydroxylase. This satisfies a need inthe art by providing a new tool in the preparation of collagenouscompositions showing various resistance times towards proteinases as itis now possible to regulate the hydroxylysine levels in thetelopeptides.

Methods for Increasing or Decreasing Hydroxyallysine Cross-Links OverAllysine Cross-Links by Means of Modulating Telopeptide LysylHydroxylase Expression

The invention provides a method of treating a fibrotic condition in amammal by administering to said mammal an effective amount of a compoundor composition which reduces the lysyl hydroxylation level of collagentelopeptides and thereby results in a collagenous matrix having adecreased ratio of hydroxyallysine cross-links to allysine cross-links.As to the exact method of administration, dose to be administered andtreatment protocol, the invention is not particularly restricted. Thesefactors depend much on factors such as the active substance orcomposition to be administered, the tissue to be treated, the patient tobe treated, the extent of the fibrosis, etc. For example, topical orsubcutanous administration would be administration routes of choice whenfibrosis occurs in skin or other easily accessible tissues.Administration by inhalation would be a preferable route ofadministration with fibrosis in lung tissue. Systemic administration,e.g. by intravenous injection or infusion, may be necessary when thefibrosis occurs in internal tissues, such as liver. The active agent maybe coupled to a means for targeting to a particular site or tissue. Theskilled person may determine for each individual case the best treatmentstrategy, with respect to route of administration, active substance orcomposition to be administered and dose and treatment protocol.

An approach to inhibit the conversion of telopeptide lysine intohydroxylysine for the preparation of collagenous materials withdecreased hydroxylysine levels is the inhibition of transcription of theresponsible telopeptide lysyl hydroxylase gene. A compound capable ofsilencing the promotor region of telopeptide lysyl hydroxylase is apotentially attractive compound for modifying the amount ofhydroxyallysine cross-links over allysine cross-links. Compoundsworthwhile to investigate are for example minoxidil and minoxidilanalogues, compounds known to inhibit the transcription of the PLOD1gene [S. Murad et al., 1994, Arch. Biochem. Biophys., 308: 42-47].

A further approach to inhibit the synthesis of telopeptide lysylhydroxylase is the inhibition of mRNA translation by means of antisenseRNA (the transcription product of the DNA antisense strand, i.e. thestrand that does not encode a protein). Transfection of the cells can bedone with naked antisense RNA, antisense RNA emulsified in or coupled tocarriers or vectors containing (parts of) the PLOD2 DNA antisensestrand.

Another approach to inhibit the conversion of telopeptidyl Lys into Hylis inhibition of the activity of the enzyme telopeptide lysylhydroxylase itself. Prolyl hydroxylase and lysyl hydroxylase have verysimilar catalytic properties (e.g. they share the same co-substrates).In addition, the inhibition patterns of prolyl and lysyl hydroxylasesare very similar as well, but differences exists in some details,suggesting that significant differences exist between the catalyticsites of said hydroxylases. For example, K, values of the aliphatic andaromatic 2-oxoglutarate analogues (see below) are distinctively higherfor lysyl hydroxylase encoded by PLOD1 than for prolyl 3-hydroxylase andprolyl 4-hydroxylase. The data that have previously been obtained withrespect to the inhibition of prolyl 3-hydroxylase, prolyl 4-hydroxylaseand helical lysyl hydroxylase encoded by PLOD1 can be used for aknowledge-based design of inhibitors of telopeptide lysyl hydroxylase.The assumption is strengthened by the observation, that thehydroxylation reaction carried out by the enzyme encoded by PLOD2 can befollowed, like that of PLODI, by measuring the decarboxylation of2-oxo-[1-¹⁴C]glutarate [Valtavaara et al., 1997, J. Biol. Chem., 272:6831-6834].

The comparable reaction mechanism of of the enzyme encoded by PLOD2 withthat of the enzyme encoded by PLODI provides a window with respect tothe design of telopeptide lysyl hydroxylase inhibitors for those skilledin the art. What follows is a description of the reaction mechanism ofthe protein encoded by PLOD2 based on previous findings for the proteinencoded by PLOD1, followed by descriptions how this reaction mechanismcan be inhibited. This should provide the skilled artisan sufficientguidance as the techniques closely parrallel experiments described inthe past with respect to inhibition of the enzyme encoded by PLOD 1.Lysyl hydroxylase acts on lysine in a reaction that requires ferrous ion(Fe²⁺), 2-oxoglutarate, molecular oxygen (0₂) and ascorbate. The2-oxoglutarate is stoichiometrically decarboxylated during hydroxylationwith one atom of the 02 being incorporated into succinate while theother is complexed to the enzyme-bound ferrous ion. The latter resultsin a highly reactive iron-oxygen complex, ferryl ion. The oxygen atom ofthe ferryl ion is subsequently incorporated into the hydroxy groupformed on the lysine residue, thereby converting the ferryl ion to theenzyme-bound ferrous ion. In the absence of a hydroxylatable substrate,lysyl hydroxylase is able to catalyze the decarboxylation reaction of2-oxoglutarate in the presence of all the co-substrates [G. Tschank etal., 1994, Biochem. J., 300: 75-79]. In this so-called uncoupledreaction, the ferry) ion is converted to Fe³⁺ and OH⁻, and the Fe³⁺ ionremains bound to the active site, making the enzyme unavailable for newcatalytic cycles until the Fe³⁺ is reduced into Fe²⁺ by ascorbate. Themain role of ascorbate in the lysyl hydroxylase reaction in vivo is thatof reactivating the enzyme after an uncoupled reaction [R. Myllyla etal., 1984, J. Biol. Chem., 259: 5403-5405]. As such, ascorbate plays ahousekeeping role of restoring the iron constituent of the enzyme to thereduced state should it become oxidized adventitiously. The uncoupledreaction (and thus the oxidation of the iron) can be enhanced bypeptides containing an unhydroxylatable sequence [D. F. Counts et al.,1978, Proc. Natl. Acad. Sci. USA, 75: 2145-2149; N. V. Rao & E. Adams,1978, J. Biol. Chem., 253: 6327-6330].

The enzymatic reaction that converts telopeptide lysine intohydroxylysine can be used for the design of compounds that inhibit theactivity of telopeptide lysyl hydroxylase without inhibiting lysyloxidase. Examples of such potential inhibitors are:

Compounds (such as aliphatic and aromatic structural analogues of2-oxoglutarate) that bind to the subsite(s) of active site of the enzymedestined for the binding of 2-oxoglutarate. The inhibition oftelopeptide lysyl hydroxylase activity by said compounds is competitivewith respect to 2-oxoglutarate.

-   -   Compounds that chelate Fe²⁺ bound in the active site of        telopeptide lysyl hydroxylase. The inhibition of telopeptide        lysyl hydroxylase activity by said compounds is competitive with        respect to the oxygen atom acceptor function of Fe²⁺ and/or with        respect to the binding of Fe²⁺ to 2-oxoglutarate.    -   Syncatalytic inactivation of telopeptide lysyl hydroxylase by        anthracyclines or coumalic acid analogues.    -   Syncatalytic inactivation of telopeptide lysyl hydroxylases by        peptides containing an unphysiologic lysine derivate in a        hydroxylatable position.    -   Hydroxylatable peptides or peptidomimetics that are competitive        with respect to the natural substrate (telopeptides) of        telopeptide lysyl hydroxylase. A selective peptide or peptido        mimetic is much less competitive with respect to the natural        substrate of lysyl oxidase.    -   Non-hydroxylatable peptides or peptido mimetics that are        competitive with respect to the natural substrate (telopeptides)        of telopeptide lysyl hydroxylase. A selective peptide or peptido        mimetic is much less competitive with respect to the natural        substrate of lysyl oxidase.    -   Compounds that compete with collagen for the peptide substrate        binding site on telopeptide lysyl hydroxylase. Possible examples        are the organophosphate-like compounds like malathion and its        oxidized derivative malaoxon, shown to inhibit helical lysyl        hydroxylase [A. Samimi & J. A. Last, 2001, Toxicol. Appl.        Pharmacol., 176: 181-186].

The uncoupled reaction of lysyl hydroxylase can be used for the designof compounds that inhibit the activity of telopeptide lysyl hydroxylase.Potent compounds are:

-   -   Non-reducing ascorbate analogues that bind to the enzyme's        active site but are not able to act as a specific alternative        acceptor of ferryl oxygen. The presence of such a compound in        the active site instead of an ascorbate (or an ascorbate        analogue capable of reducing the ferryl ion) results in the        inactivation of the enzyme by self-oxidation. The inhibition of        telopeptide lysyl hydroxylase activity by said non-reducing        ascorbate analogues is competitive with respect to ascorbate.    -   Peptides or peptido mimetics with an unhydroxylatable sequence,        capable of enhancing the uncoupled reaction of telopeptide lysyl        hydroxylase. Said inhibitors result in increased levels of        self-oxidized (non-active) levels of telopeptide lysyl        hydroxylase.

A large number of studies have been published with respect to theinhibition of prolyl hydroxylase and helical lysyl hydroxylase by meansof peptides or other compounds. What follows are a few selected examplesof studies that can be used as a starting point in the design ofinhibitors for telopeptide lysyl hydroxylase without affecting lysyloxidase. Examples of syncatalytic inactivation by peptides: V. Gunzleret al., 1988, J. Biol. Chem., 263: 19498-19504; K. Karvonen et al.,1990, J. Biol. Chem., 265: 8145-8419. Examples of syncatalyticinactivation by coumalic acid and anthracyclines: V. Gunzler et al.,1987, Biochem. J., 242: 163-169; V. Gunzler et al., 1988, Biochem. J.,251: 365-372. Examples of inhibitory competitive analogues of2-oxoglutarate and ascobate: K. Majamaa et al., 1984, Eur. J. Biochem.,138: 239-245; K. Majamaa et al., 1985, Biochem. J., 229: 127-133; K.Majamaa et al., 1986, J. Biol. Chem., 261: 7819-7823. Examples ofconformational requirements of lysyl hydroxylatable peptides: P. Jiang &V. S. Ananthanarayanan, 1991, J. Biol. Chem., 266: 22960-22967.

Apart from the knowledge-based design of inhibitors of telopeptide lysylhydroxylase, a search can be performed with a library of compounds inorder to find a compound that inhibitis the activity of telopeptidelysyl hydroxylase, but not lysyl oxidase.

A further example of inhibition of the catalytic properties oftelopeptide lysyl hydroxylase is the use of antibodies. Antibodiesdirected against the enzyme and capable of blocking the active site orinhibiting the hydroxylation by telopeptide lysyl hydroxylase otherwiseare potent inhibitors of the enzymatic reaction. These antibodies,preferably monoclonal, can be generated by immunization of mice withsynthetic peptides or peptidomimetics containing stretches of aminoacids of telopeptide lysyl hydroxylase, in particular sequences aroundthe residues responsible for the binding of Fe^(e+) or 2-oxoglutarate tothe enzyme. Promising candidate peptides or peptidomimetics for thegeneration of inhibiting antibodies are likely (but not necessarily) tobe derived from the last 60 residues at the carboxy-terminal end of theenzyme (i.e. the region containing the conserved residues known to playa role in the catalytic properties of lysyl hydroxylase encoded byPLOD1). Monoclonal antibodies can also be generated by screening phagedisplay libraries in their ability to block the activity of telopeptidelysyl hydroxylase. Antibodies not directed to the active site butdirected against parts of the enzyme that are important for substratebinding are also potent inhibitors of the enzymatic reaction. Inaddition, antibodies directed towards the collagen telopeptides are alsoexpected to inhibit the hydroxylation reaction of telopeptide lysylhydroxylase by means of steric hindrance. Besides monoclonal orpolyclonal antibodies, intracellular antibodies (intrabodies) can beused. Such intrabodies are encoded by engineered genes that areexpressed within the cells of interest [I. J. Rondon & W. A. Marasco,1997, Annu. Rev. Microbiol., 51: 257-283].

Alternatively, aptamers can be used to inhibit the reaction catalyzed bytelopeptide lysyl hydroxylase. Aptamers are selected nucleic-acidbinding species that bind to a target molecule with high affinity andspecificity (the Latin word “aptus” means “to fit”). Nucleic acidaptamers that bind to telopeptide lysyl hydroxylase can be readilyselected by the SELEX process, a technique for screening very largecombinatorial libraries of oligonucleotides by an iterative process ofin vitro selection and amplification [S. D. Jayasena, 1999, Clin. Chem.,45: 1628-1650]. The library typically contains 10¹⁴-10¹⁵ random DNAsequences flanked by two fixed sequence regions. Sequences that bind tothe target molecule (the latter being fixed on a solid support) areseparated from sequences that do not bind by a simple washing step. Thepopulation of sequences bound to the target is amplified by PCR usingprimers to the two fixed sequence regions. The enriched library can beused for the next selection/amplification cycle. The enrichmentefficieny of high-affinity binders is governed by the stringency ofselection at each round. The enriched library is cloned and sequenced toobtain the sequence information of each member. The generated aptamershave to be screened for their ability to inhibit the target enzyme bymeans of an assay designed to measure the activity of telopeptide lysylhydroxylase.

In yet another approach to inhibit the conversion of telopeptide lysineinto hydroxylysine is the delivery of constructs containing atelopeptide lysyl hydroxylase that is able to bind telopeptides but isnot capable to convert the lysine of the telopeptides intohydroxylysine. Such an exogenous telopeptide lysyl hydroxylase iscompetitive to endogenous telopeptide lysyl hydroxylase with respect toits natural substrate (telopeptides). For said construct telopeptidelysyl hydroxylase can be used that is mutated by means of site-directedmutagenesis. Candidate residues for site-directed mutagenesis are themutated residues found in Bruck syndrome. Other candidate residues forsite-directed mutagenesis are the residues that are needed for the fullactivity of helical lysyl hydroxylase [A. Pirskanen et al., 1996, J.Biol. Chem., 271: 9398-9402] and that are conserved in the lysylhydroxylase encoded by PLOD2. Especially interesting are the threeligands needed for the binding of Fe^(z+) to the catalytic site of lysylhydroxylase (for helical lysyl hydroxylase encoded by PLOD1 this isHis-638, Asp-640 and His-690; numbering begins with the first residue inthe processed polypeptide) or the residue that is responsible for thebinding of 2-oxoglutarate to the enzyme (which is Arg-700 for thehelical lysyl hydroxylase encoded by PLOD 1) [K. Passoja et al., 1998,FEBS Letters, 434: 145-148]. The same residues are conserved in PLOD2.Residues that are also of potential interest are glycosylatedAsn-X-Thr/Ser sequences: glycosylated lysyl hydroxylase encoded by PLOD1has a higher activity than its de-glycosylated counterpart [R. Myllylaet al., 1988, Biochem. J., 253: 489-496]. It thus seems thatasparagine-linked oligosaccharides are required to obtain maximum lysylhydroxylase activity. Two potential attachment sites forasparagine-linked oligosaccharides of the lysyl hydroxylase encoded byPLOD2 have an homologous location in the sequence of the helical lysylhydroxylase encoded by PLOD1. Other residues of potential interest arethe cysteines of lysyl hydroxylase 2. These examples should not beconstrued as limiting.

A further embodiment of the subject invention for inhibiting theconversion of telopeptide lysine into hydroxylysine is theadministration of an effective quantity of peptides comprising ahydroxylatable Lys. Peptides which act as enzyme substrates reduce thelevels of enzyme available for hydroxylating collagen telopeptides. Amethod for the delivery of such peptides into the cells is the deliveryof plasmid constructs containing the nucleotide sequence encoding forsuch peptides.

Pathological Levels of Hydroxallysine Cross-Links Results in an UnwantedAccumulation of Collagen Molecules (Fibrosis)

In abnormal wound healing of the skin, such as in hypertrophic scarring,large amounts of hydroxyallysine-derived cross-links (such as DHLNL) areseen [A. J. Bailey & N. D. Light, 1985, Ciba Found. Symp., 114: 80-96].A predominance of DHLNL is also found in collagen produced afterwounding of the corneal stroma; the resulting scar shows markedlyincreased levels of hydroxyallysine derived cross-links at the expenseof allysine cross-links [D. J. Cannon & S. Cintron, 1975, Biochim.Biophys. Acta, 412: 18-25]. The pioneering studies on elevatedhydroxyallysine-derived cross-links in abnormal scarring were laterconfirmed, followed by reports on increased hydroxyallysine-derivedcross-links in other (mainly fibrotic) disorders, such as various lungdiseases (respiratory distress syndrome, idiopathic pulmonary fibrosis,hypersensitivity pneumonitis, respiratory bronchiolitis, silicosis andbleomycin-induced lung fibrosis), chronic adriamycin nephropathy (anexperimental model resulting in non-immunologic glomerulosclerosis andinterstitial fibrosis), infarct scar of the myocardium, jointcontractures, vessel luminal narrowing, lipodermatosclerosis,annulo-aortic ectasia, fibrotic lesions of Dupuytren's disease, skin ofpatients with lipoid proteinosis, diabetes, skin fibrosis due tochromoblastomycosis infection, skeletal muscle injury, tendonhypertrophy and various liver diseases such as in alveolarechinococcosis (a dense and irreversible fibrosis), hepatocellularcarcinoma, alcoholic cirrhosis or cirrhotic livers induced by viralhepatitis or by Schistosoma mansoni. From this abundant amount of dataon elevated hydroxyallysine cross-link levels in fibrotic tissues we canconclude that one of the characteristics of fibrotic lesions is anupregulation of telopeptide lysyl hydroxylase.

In recent years, it has been suggested that the relative (and absolute)amount of hydroxyallysine cross-links are adequate biomarkers for theaccumulation of collagen in lung and liver fibrosis [J. A. Last et al.,1990, Am. Rev. Respir. Dis., 141: 307-313; S. Ricard-Blum et al., 1995,Parasite, 2: 113-1181 As the same is seen in other fibrotic tissues(such as skin and kidney), it was actually stated that “It is possiblethat organ fibrosis is a unique process ultimately associated with achange in cross-linking whereby the proportion of the allysinecross-links decreases in favor of the hydroxyallysine-derivedcross-links” [J. Brinckmann et al., 1996, J. Invest. Dermatol., 107:589-592]. Thus, hydroxyallysine cross-links are implicated in thepathogenesis of fibrosis. As a matter of fact, hydroxyallysinecross-link levels might be an important criterion in assessing theirreversibility of fibrosis. The validity of this statement isstrengthened by cross-link patterns seen in acute (self-limiting) and aprogressive forms of fibrosis. Collagen produced in response to aninjury of skin is initially stabilized by DHLNL, a cross-link derivedfrom hydroxyallysine. In the early stages of wound healing, the collagenof both forms of fibrosis possess DHLNL as the major cross-link, butafter a few months fherei.s an approximately equal proportion of HLNL.Subsequently, acute and progressive fibrosis follow a different course.In hypertrophic scars, a progressive form of skin fibrosis, the 1:1ratio of the two cross-links is retained. In contrast, the cross-linkpattern in the self-limiting form of fibrosis gradually reverts tonormal, i.e. there is a disappearance of hydroxyallysine derivedcross-links and replacement by allysine derived cross-links. Inaddition, the HLNL of old hypertrophic scars is derived fromhydroxyallysine, and therefore stabilized by undergoing the Amadorirearrangement. The HLNL of normal scars is like normal dermis in beingalmost entirely derived from allysine [A. J. Bailey & N. D. Light, 1985,Ciba Found. Symp., 114: 80-96].

The data mentioned in this paragraph provides additional evidence forour statements that collagen cross-linked by means of hydroxyallysinederived cross-links is more difficult to degrade than collagencross-linked by means of allysine derived cross-links. The data indicatethat the type of cross-links provides a mechanism for regulating therate of collagen catabolism: collagen with hydroxyallysine cross-linksis less susceptible to proteolytic degradation than collagencross-linked by allysine residues. Clearly, the production of collagencontaining telopeptide lysine instead of telopeptide hydroxylysine wouldbe beneficial for treating fibrotic conditions. Inhibition oftelopeptide lysyl hydroxylase (to enhance the formation of allysinecross-links at the expense of hydroxyallysine cross-links) is anattractive way for interfering with a fibrotic respons by reducing theamount of hydroxyallysine derived cross-links over allysine-derivedcross-links, making the collagen more susceptible to proteolyticdegradation. In the next paragraph we will show that PLOD2, encodingtelopeptide lysyl hydroxylase, is indeed highly expressed in fibroticcells.

Fibrotic Cells Contain High Levels of PLOD2 mRNA

Clearly, fibroblasts in fibrotic tissues (the so-called myofibroblasts)are fundamentally different from that of normal fibroblasts:myofibroblasts synthesize collagen with increased hydroxylysine levelsof the telopeptides. Such collagen is destined to become irreversiblyincorporated into the collagen network of the tissue by means ofhydroxyallysine cross-links. The fact that HP, the maturation product ofDHLNL, might serve as a permanent marker of a fibrotic event indicatesthat such cross-linked collagen molecules show a low to negligible rateof degradation. We have concluded in the previous paragraphs thathydroxylation of the telopeptide lysine is controlled by telopeptidelysyl hydroxylase, and that PLOD2 encodes for telopeptide lysylhydroxylase. Therefore, PLOD2 must be overexpressed in myofibroblasts.We have checked this by measuring mRNA levels of PLOD2 in normalfibroblasts and in myofibroblasts by means of real-time PCR techniques.To strengthen our conclusion, that telopeptide lysyl hydroxylase is akey enzyme in fibrosis, we also measured mRNA levels of PLOD1, PLOD3,and collagen type I (COL1A1). FIG. 5 shows that myofibroblasts have inmean a 40-fold increase of PLOD2 mRNA levels compared to fibroblasts. Incontrast, only a 4-fold increase was observed in PLOD1 and COL1A1 mRNAlevels. PLOD3 levels were in most cases not elevated. The data indicatethat telopeptide lysyl hydroxylase is highly upregulated in fibrotictissues.

Measurement of PLOD2 mRNA, Teloptide lysyl Hydroxylase Protein Level orTelopeptide Lysyl Hydroxylase Activity Level as a Tool to Diagnose orMonitor Fibrotic Processes

The invention provides a method for diagnosing and/or monitoring theoccurrence or state of a fibrotic process in a mammal comprising takinga sample from said mammal, analyzing said sample to determine theexpression level of a PLOD2 gene and comparing said expression levelwith a standard. Suitable samples are tissue samples, in particular fromtissues at risk for, or involved in, fibrotic processes. Suitablestandards represent the expression level of a PLOD2 gene in normaltissues, i.e. not affected by fibrotic processes.

Detection of transcriptional acitivity of the gene PLOD2 may be achievedby assaying the level of mRNA derived from PLOD2 (e.g., by Northern blotanalysis, mRNA analysis by competitive PCR or real time PCR), theprotein level of telopeptide lysyl hydroxylase (e.g., by Western blotanalysis, or by immunoassays such as ELISA), or the level of functionalenzymatic activity of telopeptide lysyl hydroxylase (e.g., by means ofhydroxylatable peptides).

In the first approach, transcriptional activity of the PLOD2 codingregion can be assessed by hybridization assays. For example, RNA can beisolated and analyzed by Northern blot using a probe homologous to thetelopeptide lysyl hydroxylase coding sequence or particular portionsthereof. Estimation of mRNA levels can also be achieved by usingPCR-based technologies, such as the conversion of mRNA to cDNA byreverse transcriptase, followed by e.g. competitive PCR or real-timePCR. A description of a real-time PCR to measure PLOD2 levels is givenin one of the Examples.

In the second approach, the expression of the enzyme product (reflectingtranslational activity) can be assessed immunologically, for example byWestern blots, immunoprecipitation, immunoassays such as enzyme-linkedimmunoassays and the like. The antibodies can be polyclonal, monoclonal,or chimeric of nature. The antibodies can be obtained by immunization ofanimals with the native or denatured enzyme or fragments thereof (suchas synthetically manufactured peptides). Alternatively, the antibodiescan be raised by means of the phage display method. The enzyme productcan also be assessed by means of aptamers based on DNA/RNA sequences [S.D. Jayasena, 1999, Clin. Chem., 45: 1628-1650].

In the third approach, the expression of the enzyme product can beassessed by methods reflecting the enzymatic activity of the enzyme.Such methods are described in the next chapter.

High Through-Put Assays for Measuring Telopeptide Lysyl HydroxylaseActivity

The invention provides an assay for screening compounds or compositionsto determine their effect on telopeptide lysyl hydroxylase activitycomprising contacting under enzymatically functional conditions acompound or composition to be tested with a PLOD2-encoded telopeptidelysyl hydroxylase enzyme and a suitable substrate for this enzyme, anddetermining the level of lysyl hydroxylation of the substrate comparedto the level of lysyl hydroxylation of the substrate in the absence ofthe compound or composition to be tested.

The following description illustrates a method which can potentiallylead to a high through-put assay for measuring the activity oftelopeptidyl lysyl hydroxylase. Such an assay can be used for thescreening of compounds in order to determine their antagonistproperties, or as a tool to diagnose or monitor fibrotic processes.

A biotinylated peptide containing a telopeptide-like sequence containingat least one hydroxylatable Lys is subjected to incubation withtelopeptide lysyl hydroxylase. The resulting mixture is treated withperiodate or other suitable oxidizing agent. The 2-amino alcohol of Hylin peptides has been shown to undergo rapid periodate oxidation tocreate an aldehyde [D. D. van Slyke et al., 1941, J. Biol. Chem., 141:681-705]; the same occurs with peptides with a N-terminal Ser orN-terminal Thr. By designing a peptide substrate lacking N-terminal Seror Thr in the peptide, only peptides containing a Hyl will form analdehyde by means of periodate treatment. The aldehyde is then reactedwith a tagging group, for instance in the form of a hydrazide, R′CONHNH₂to form a hydrazone, R′CONHN=CH-peptide. R′ can be any variety of usefulgroups, such as Lucifer Yellow, Texas Red or Cascade Blue. Thebiotinylated peptide can be separated from the remaining reactionmixture by immobilization based on the strong interaction of biotin withavidin or streptavidin. Other options are e.g. the use of peptidescontaining a repetitive His-sequence in combination with Ni^(t+)carriers or SAMA-peptides in combination with maleimide carriers.Measuring the fluorescence of the tag attached to Hyl providesinformation about the conversion of the Lys of the peptide into Hyl bytelopeptide lysyl hydroxylase. Tags can also be used that are suitablefor colorimetric or radioactive measurements.

It should be stressed, that the oxidation of Hyl by periodate results inthe stoichiometric release of formaldehyde. 4-Amino-3-pentene-2-one(fluoral P) is reported to selectively react with formaldehyde to form afluorescent dihydropyridine product [H. Tsuchiya et al., 1994, Analyst,119: 1413-1416], even when aldehyde concentrations 2000 times that ofdetectable formaldehyde are present. Thus, measuring the release offormaldehyde is another method to provide information whether the Lys ofthe peptide is converted into Hyl by telopeptide lysyl hydroxylase.

In yet another format, energy-transfer substrates can be prepared formeasuring whether a Lys or a Hyl is present in the peptide. In this typeof substrate, two chromophoric groups that form a Forster energydonor-acceptor pair are placed at opposite ends of a peptide. Thefluorescence emission of the donor overlaps the absorption spectrum ofthe acceptor, causing the fluorescence of the donor to be quenched whilethe substrate remains intact. When the intervening peptide region iscleaved by a proteinase, relief of the strongly distance-dependentquenching provides the means to follow this activity. In concreto, aenergy-transfer substrate (a peptide containing a telopeptide-likesequence containing at least one hydroxylatable Lys and containing afluorophore and a quencher) is subjected to telopeptide lysylhydroxylase followed by digestion with trypsin or lysyl endopeptidase.The latter cleaves the peptide bond at the C-terminal end of Lys;trypsin cleaves the peptide bond on the C-terminal side of Lys and Arg.Hydroxylation of Lys residues reduces their susceptibility to digestionby trypsin or lysyl endopeptidase [M. S. Molony et al., 1998, Anal.Biochem., 258: 136-137]. In this format, diminished increase offluorescence is seen at a given time when the Lys is converted into Hyl.

Other high through-put formats may be based on antibodies or aptamersrecognizing the non-hydroxylated peptide but not the hydroxylatedpeptide or vice versa.

EXAMPLES Example 1

Pepsin Digestion of Normal and Bruck Syndrome Bone Shows Differences inCollagen Degradation by Proteolytic Enzymes and Differences in CollagenPacking

Bruck syndrome and normal bone was demineralized at 4° C. with 0.5 MEDTA, 0.05 M Tris-HCI, pH 7.5 over 2 weeks. Demineralized Bruck syndromeand normal bone was incubated for 24 h at 4° C. with 0.5 M acetic acid(HAc) or with pepsin (enzyme:substrate ratio 1:10, w/w) in 0.5 M HAc.The solubilized collagen (present in the supernatant) was separated fromthe insoluble collagen matrix (containing the non-solubilized collagen)by means of centrifugation; both were hydrolyzed with 6 M HCI in Teflonsealed glass tubes (110° C., 20-24 h). The amount of thecollagen-specific amino acid hydroxyproline (Hyp) was measured withreversed-phase high-performance liquid chromatography [R. A. Bank etal., 1997, Matrix Biol., 16: 233-243]. The amount of solubilizedcollagen was expressed as a percentage of total collagen using theequation Hyp_(sup)/(Hyp₁₀+Hyp_(SU)p)×100% where Hyp_(SU)p is the amountof Hyp in the supernatant and Hyp_(fes) the amount of Hyp in theresidual tissue.

Collagen solubility in 0.5 M acetic acid was 7% and 1% for Brucksyndrome and normal bone, respectively. Treatment with pepsin resultedin the release of 65% of the collagen from Bruck syndrome bone, whereastreatment with pepsin resulted in the release on only 5% of the collagenfrom normal bone. Clearly, the collagen molecules in the fibrils inBruck syndrome bone are more prone to degradation by proteinases. As thetriple helix of collagen type I in Bruck syndrome is normally modified,the increased release of collagen by pepsin of Bruck syndrome bone isdue to the replacement of hydroxyallysine cross-links by allysinecross-links.

The pepsin-solubilized collagen of normal bone and Bruck syndrome bonewas subjected to SDS-polyacrylamide gel electrophoresis and subsequentlystained with Coomassie Brilliant Blue; the staining pattern of normalbone revealed three 0-bands (p1,1, (31,2 and p2,2 in a 1:1:1 ratio)whereas the staining pattern of Bruck syndrome bone revealed two p-bands(p1,1 and p1,2 in a 1:2 ratio). The p-band patterns show that there aredifferences in the packing of intrafibrillar collagen molecules betweennormal and Bruck syndrome bone.

Example 2

Hydroxyproline Measurements in Urine Revealed that in vivo Degradationof Bone collagen is Enhanced in Bruck Syndrome

Urine.samples .(500 μl) were hydrolyzed in an oven (110° C.; 20-24 h)with 500 μl 12 M HCI in 5 ml Teflon sealed glass tubes. After drying(SpeedVac, Savant), the hydrolysates were dissolved in 1 ml water, anddiluted 400 times in 0.1 M borate buffer pH 9.5. A 200 μl sample wasmixed with 25 μl o-phthaldialdehyde (OPA) reagent (30 mg OPA+15 plR-mercaptoethanol in 1 ml acetone) and reacted for 1 min at roomtemperature. The reaction mixture was mixed with 25 pl iodoacetamide (80mglml acetone) and incubated at room temperature for at least 30 sec toremove excess [3-mercaptoethanol. Subsequently, the secondary aminoacids hydroxyproline (Hyp) and proline (Pro) were derivatized with 50 pl6 mM 9-fluorenylmethyl chloroformate in acetone for 5 min at roomtemperature. Immediately thereafter, the sample was extracted twice with700 μl diethyl ether to terminate the reaction and to remove excessreagent. After the addition of 400 μl 25% (vlv) acetonitrile in 0.1 Mborate buffer pH 8.0, a 50 μl aliquot of the derivatization mixture wasinjected into the HPLC system. In this way, 0.0208 41 of the originalurine sample was applied onto the column. Reversed-phase chromatographyof the samples on a Micropak ODS-80TM column (150 mm×4.6 mm; Varian,Sunnyvale, Calif., USA) was performed as described elsewhere [R. A. Banket al., 1996, Anal. Biochem., 240: 167-176]; Hyp calibration wasperformed with an amino acid standard for collagen hydrolysates obtainedfrom Sigma (A-9531; St. Louis, Mo., USA).

FIG. 1A-B shows the urinary excretion of Hyp and the Hyp/Pro ratio inBruck syndrome patients versus controls as a function of age. Allpatients show a high excretion of Hyp, indicating a high degradationrate of collagen. As most of the collagen degradation products in urineare derived from bone [M. S. Calvo et al., 1996, Endocrine Reviews, 14:333-368], the data show that Bruck syndrome patients have an increasedturnover of bone collagen. This is due to the replacement ofhydroxyallysine cross-links by allysine cross-links in Bruck syndromebone, making the collagen network more susceptible towards proteinases.

Example 3

Mutation Analysis of the PLOD2 Gene of Bruck Syndrome Patients Revealsthat PLOD2 is Telopeptide lysyl Hydroxylase

Amplification of the individual exons of PLOD2 was carried out with theprimers presented in table 1. The PCR mix consisted of 5 41 TaKaRa 10×PCR buffer, 8 μl of of mixture containing the four dNTPs (2.5 mM each),1 μl forward primer and 1 μl reverse primer (50 each), 0.5 μl TaKaRa LaTaq polymerase (50 U/μl), 2.5 μl DNA (200 ng/μl, 5 μl DMSO and 27 μlH₂O. Thirtyfive cycles of amplification were carried out. Each cycleconsisted of: 1 min denaturation at 94° C., 0.5-1.5 min at 56-60° C. forannealing (see table for the exact condition per primer set) and 1 minat 68° C. for the extension. The amplified exons were purified with theQiagen PCR purification kit; 10 ng of each exon was subjected to a cyclesequence PCR using the ABI PRISM™ BigDye Termination Cycle SequencingReady Reaction Kit and analyzed by means of capillary electrophoresisusing the ABI PRISM™ 310 apparatus. TABLE 1 Primers used for theamplification of the individual exons of PLOD2 Product Annealing ExonForward primer Reverse primer length temperature Promoter5′ CTCCCAAAGCTAAGTGCAGG 3′ 5′ AGACAGGGATTCCAGGGGT 3′ 524 bp 56° C. 30″(SEQ ID NO:4) (SEQ ID NO:23)  1 5′ GTCTCTGCGTTCTCGCGAGA 3′5′ AAGGGCTGTTGGATGAATGAAC 3′ 260 bp 56° C. 1′30″ (SEQ ID NO:5) (SEQ IDNO:24)  2 5′ TGAGGTCTCAATTACTGTAGTGA 3′ 5′ CTTCCTTGTGAGGATTACAGATT 3′27.2 56° C. 1′30″ (SEQ ID NO:6) (SEQ ID NO:25)  35′ GTACTGTTCAAGTTGATGATGTC 3′ 5′ GCCACCGTGCCCAACCATATT 3′ 334 bp 56° C.30″ (SEQ ID NO:7) (SEQ ID NO:26)  4 5′ ATGGTTTATGTGCCTAGATTCTGA 3′5′ GGAACACCAACTCACATAATACA 3′ 390 bp 56° C. 1′30″ (SEQ ID NO:8) (SEQ IDNO:27)  5 5′ TTCTTTCATGGTGAGC′TGTGA 3′ 5′ TGATATCCAGCCAGGTGACA 3′ 442 bp56° C. 30″ (SEQ ID NO:9) (SEQ ID NO:28)  6 5′ GCAACTATCGCAGTTTCTACCT 3′5′ CCAAATGGACATAACAAAGGAAAG 3′ 331 bp 56° C. 30″ (SEQ ID NO:10) (SEQ IDNO:29)  7 5′ CACATACACACACAGACACACG 3′ 5′ AAAGGCTATCACTCTGCTGAGG 3′ 379bp 64° C. 30″ (SEQ ID NO:11) (SEQ ID NO:30)  85′ TAAAGGAATATACCTGCTGCAGA 3′ 5′ ATTCCACTTACATCTACTGCAGA 3′ 234 bp56° C. 1′30″ (SEQ ID NO:12) (SEQ ID NO:31)  9 5′ TTTCAAGTGTTAGAGAACTGCCA3′ 5′ CCACTGAACTTAACCCAATGAAT 3′ 392 bp 56° C. 1′30″ (SEQ ID NO:13) (SEQID NO:32) 10 5′ TCTAAGATTTCTAGGCTACAGGC 3′ 5′ GTTGGCTACTGCATACGCAAAC 3′633 bp 60° C. 30″ (SEQ ID NO:14) (SEQ ID NO:33) 115′ CAGAAAAGTATGCTAGAGAACCA 3′ 5′ GTAGAACATAACTAAGTTCCCTC 3′ 336 bp56° C. 1′30″ (SEQ ID NO:15) (SEQ ID NO:34) 12 5′ CAGGTTTGTTGAATGAGCTTTCT3′ 5′ AGGATTCCAAGTGGTCTTGGG 3′ 398 bp 60° C. 1′30″ (SEQ ID NO:16) (SEQID NO:35) 13 5′ GGGGCAGTGGTTfATCTCCTA 3′ 5′ CACAGTGACACACCAACTGGT 3′ 421bp 60° C. 1′30″ (SEQ ID NO:17) (SEQ ID NO:36) 13A5′ AGAATACCTGAGAGAGCGGGT 3′ 5′ ACGCAAACACACAGATGACTGA 3′ 265 bp 60° C.1′30″ (SEQ ID NO:18) (SEQ ID NO:37) 14 5′ CAGTTGAGTGTCAGTGCTATCT 3′5′ CTGGTGTGAGACAGTATCTCAT 3′ 492 bp 60° C. 1′30″ (SEQ ID NO:19) (SEQ IDNO:48) 15 5′ ATAAGCATATTCAGAACCAGGCA 3′ 5′ CTCCACTTTCACATCTTCTGTG 3′ 340bp 60° C. 1′30″ (SEQ ID NO:20) (SEQ ID NO:39) 165′ TCATCAATTCTGAGGTGCACCA 3′ 5′ AGAAACCCGCCCAAACTAAT 3′ 501 bp 56° C.30″ (SEQ ID NO:21) (SEQ ID NO:40) 17 5′ AGCAGATGATATACCACATTGGA 3′5′ GTTCATGCCAGTCATTCATCCA 3′ 896 bp 60° C. 30″ (SEQ ID NO:22) (SEQ IDNO:41) 18 5′ AGCAGATGATATACCACATTGGA 3′* 5′ GTTCATGCCAGTCATTCATCCA 3′896 bp 60° C. 30″ (SEQ ID NO:22) (SEQ ID NO:41) 195′ AGCAGATGATATACCACATTGGA 3′* 5′ GTTCATGCCAGTCATTCATCCA 3′ 896 bp60° C. 30″ (SEQ ID NO:22) (SEQ ID NO:41)Primers used for sequencing are shown in bold.*Sequence primer for exon 18 is 5′ GGTCTTTGCAGGCTATTATA 3′ and for exon19 is 5′ GCTCAAATGACATAATTTG (SEO ID NO:42)

Sequence analysis of two Bruck syndrome patients of family PM, showed aG→T nucleotide missense mutation resulting in a Gly→Val amino acidsubstitution in the sequence GGYENVPT (SEQ ID NO:1) (the mutated Gly isunderligned). This mutation was found on both alleles. Both parents werecarrier of this missense mutation (see FIG. 3). In one Bruck syndromepatient of family DR a CST nucleotide missense mutation is seenresulting in a Thr→lle amino acid substitution in the sequence GGYENVPT(SEQ ID NO: 1). The patient was homozygous for the mutation while bothparents and a healthy sister were heterozygous for this mutation (seeFIG. 4). The two different point mutations found in family PM and DRwere situated in a sequence that shows 100% homology between thedifferent PLODs and between different species. This suggests animportant role of this region in the function of lysyl hydroxylases ingeneral and that of PLOD2 in particular. Bruck syndrome is characterizedby defective telopeptide lysyl hydroxylase activity [R. A. Bank et al.,1999, Proc. Natl. Acad. Sci. USA, 96: 1054-1058]. The above describedmutations show that PLOD2 encodes telopeptide lysyl hydroxylase.

The knowledge that PLOD2 encodes for telopeptide lysyl hydroxylaseprovides the skilled artisan the necessary information for increasing ordecreasing the hydroxylysine levels in the telopeptides of collagen byincreasing or decreasing the enzyme activity level of telopeptide lysylhydroxylase in cells during collagen synthesis. The synthesized collagencan subsequently be harvested by standard purification methods for thepreparation of collagenous materials (such as collagen matrices assupports for new tissue growth, or collagen-based wound dressings) withincreased or decreased turnover times.

Example 4

Preparation of Collagenous Matrices with Increased or Decreased TurnoverTimes

A number of methods has been disclosed to isolate collagen from tissues.This collagen can subsequently be used for the preparation ofcollagen-based devices. Mostly, skin or tendons are used for thepreparation of collagen. The collagen in skin has a very lowhydroxyallysine cross-linking. Indeed, collagen in skin has a shorthalf-life. Tendons show various levels of hydroxyallysine cross-links,depending on the anatomical position of the tendon (see e.g. R. A. Banket al., 1999, Arthr. Rheum., 58: 35-41). The collagen in tendon shows amuch higher half-life. Bone shows intermediate levels of hydroxyallysinecrosslinks. The amount of hydroxyallysine crosslinks further depends onbone type (cortical or trabecular) and skeletal site (see e.g. L. Knott& A. J. Bailey, 1999, British Poultry Science, 40: 371-379). By mixingthe collagen derived from tissues containing low and highhydroxyallysine crosslinks in various ratios, collagen compositions areobtained that can be used for the manufacturing of collagenous matricesshowing increased or decreased turnover times.

Example 5

Expression of Recombinant PLOD2 in Cells to Enhance lysyl HydroxylationLevels in Telopeptides

The human PLODS signal peptide sequence followed by a His₆ tag sequencewas linked to the cDNA sequence of human PLOD2B starting from the likelyamino-terminal end of the molecule. Four overlapping oligonucleotides,covering the nucleotide sequence for the PLOD1 signal peptide and a His₆tag flanked by Nhel and BamHl restriction sites, were annealed and theprotruding 5′ ends were filled in by cloned pfu polymerise (Stratagene).The resulting double-stranded, blunt-ended product was ligated to theEcoRV site of the pMOSBlue vector (Amersham). The human PLOD2B cDNAsequence covering nucleotides 76 to 2283 was cloned into the BamHl/Kpnlsites of the construct. Finally, an expression construct (FIG. 6) wascreated by cloning the PLOD2B cDNA sequence with the PLOD1 signalpeptide into the Nhel/Kpnl site of pcDNA3.1 (−) (Invitrogen). A similarconstruct for splice variant PLOD2A, lacking exon 13A, was obtained byreplacing a Pacl/BsrGI fragment in the PLOD2B nucleotide sequence forthe same fragment from the PLOD2A sequence. The expression constructs,called pDHPL2b.5 and pDHPL2a.4, were confirmed by sequencing. Therecombinant proteins contain a His₆ tag at the N-terminus after signalpeptide cleavage. HEK293 cells were cultured in DMEM supplemented with10% FBS in 5% C02 until they reached confluency. For transfection cellswere plated in 10 cm2 wells at such a density that 70% confluence wasreached after 16 hrs of incubation at 37° C. Two hours prior totransfection, fresh medium was added to the cells. The cells weretransfected with a total of 1 μg of each plasmid using the lipid-basedFuGENE™ 6 transfection reagent (Roche Molecular Biochemicals,Indianapolis, Ind., USA) in a ratio of 1:4 (μg DNA: μl FuGENE). Toobtain stable HEK293 clones expressing TLH the cells were diluted 100times 24 hours after transfection and plated in 10 cm2 wells inselective medium containing 700 p.glml geneticine (Invitrogen). Aftertwo weeks culturing in selective medium single clones were picked andscreened for TLH expression by Western blotting. Considerable amounts oftelopeptide lysyl hydroxylase were observed in both the cytosol and inthe culture medium.

The same construct can be used to transfect collagen-producing cells inorder to obtain cells that constitutively express telopeptide lysylhydroxylase encoded by PLOD2. By doing so, collagen is secreted showinghigh levels of hydroxylysine in the telopeptides, being the molecularbasis for the generation of collagen matrices with enhanced stabilityagainst proteinases. The secreted collagen can be purified by a varietyof methods, such as those described by D. K. Furuto & E. J. Miller(1987, Methods Enzymol., 144: 41-61), and used for the preparation ofscaffolds.

Example 6

Stimulation of Endogenous PLOD2 Expression in Cells to Enhance LysylHydroxylation Levels in Telopeptides

Human skin fibroblasts were cultured in 25 cm2 flasks in DMEM (Gibco)supplemented with 10% FBS in 5% CO₂. At near confluency the fibroblastsand myofibroblasts were incubated for 50 hours in medium containing 1, 5or 10 nM human recombinant TGF-M, -R2 or -13. As a control, human skinfibroblasts were incubated for 50 hours in medium without the additionof TGF-R. At the end of the incubation period, the cells were washedwith PBS and lysed with 600 μl RLT-buffer (RNeasy kit, Qiagen). RNA wasisolated following the manufacturers protocol and subsequently reversetranscribed into cDNA (first strand cDNA synthesis kit, Roche MolecularBiochemicals). The levels of PLOD2B mRNA in the untreated and TGF-1.treated cells were quantified using real-time PCR as described inexample 8.

FIG. 9 shows that treatment of fibroblasts with TGF-M, -R2 or -R3increases the PLOD2B mRNA levels about 20-fold. TGF-R is thus an exampleof an agent that increases PLOD2B mRNA expression and can thus be usedto increase cross-linking derived from the hydroxyallysine pathway. Suchcollagen can be purified and subsequently be used for the preparation ofcollagen scaffolds showing an increased resistance towards proteinases.

Example 7

Inhibition of Teloptide Lysyl Hydroxylase Activity Levels in Cells toDecrease Iysyl Hydroxylation Levels in Telopeptides

Chondrocytes from the metacarpophalangeal joint of calves (12-14 monthsold, local slaughterhouse) were isolated by collagenase digestion:cartilage slices were minced and digested overnight at 37° C. in 0.14%(w/v) collagenase (Worthington CLS2) in Dulbecco's modified Eagle'smedium (DMEM). After filtration of the suspension, cells were washedsuspended in 1.2% (w/v) alginate (Keltone LVCR) in 0.9% NaCl at adensity of 4×106 cells/ml, which was passed dropwise through a 22-gaugeneedle into 102 mM CaCI₂. After 10 min of polymerization, beads werewashed in 0.9% (wlv) NaCl (three times) and finally in complete medium:DMEM-Glutamax (Gibco BRL) supplemented with 100 U/ml ofpenicillin/streptomycin, 10% (v/v) foetal calf serum and 50 μg/mlascorbic acid. The cells were cultured at 10 beads per 0.5 ml medium ina humid atmosphere of 5% CO2 in air at 37° C.; the medium was refreshedtwice weekly. Minoxidil was dissolved in complete medium and added tothe culture after 7 days of preculture under control conditions.Harvested beads were washed with 0.9% NaCl containing 10 mM CaCl₂ andhydrolyzed in 900 l 6 M NCI at 108° C. for 20-24 h. An aliqout of thehydrolysate was subjected to amino acid analysis as decribed by R. A.Bank et al. [1996, Anal. Biochem., 260: 167-176]. Based onhydroxyproline levels, amounts of collagen were calculated, assuming 300hydroxyproline residues/triple helix. Another aliquot was subjected tocrosslink analysis as described by B. Beekman et al. [1997, Exp. CellRes., 237: 135-141]. Crosslinks were expressed as amount of residues percollagen molecule.

The amount of pyridinolines (HP and LP) in alginate beads cultured inthe presence of 1.0 mM or 2.0 mM minoxidil was in mean around 0.15residues/collagen molecule after a culture period of 20-50 days, whereasthe amount of pyridinolines in cultures treated with 0.3 mM minoxidilwas in said culture period in mean 0.38 residues/collagen molecule. Thisshows that increased concentrations of minoxidil reduces the lysylhydroxylation level of the telopeptides, molt likely by means ofinhibiting the expression of PLOD2.

To substantiate that minoxidil suppresses the expression of PLOD2, humanskin fibroblasts and myofibroblasts were cultured in 25 cm2 flasks inDMEM (Gibco) supplemented with 10% FBS in 5% CO₂. At near confluency thefibroblasts and myofibroblasts were incubated for 41 hours in mediumcontaining 1 mM minoxidil. Minoxidil was dissolved at room temperaturein medium with 10% FBS for 8 hours which was filtered prior to use. As acontrol both cell types were incubated for 41 hours in medium withoutminoxidil. At the end of the incubation period, the cells were washedwith PBS and lysed with 600 μl RLT-buffer (RNeasy kit, Qiagen). RNA wasisolated following the manufacturers protocol and subsequently reversetranscribed into cDNA (first strand cDNA synthesis kit, Roche MolecularBiochemicals). The levels of PLOD2B mRNA in the untreated andminoxidil-treated cells were quantified using real-time PCR as describedin example 8.

FIG. 8 shows that treatment of myofibroblasts with minoxidil reduces thePLOD2B mRNA levels about 15-fold. The PLOD2B mRNA levels in fibroblastsis much lower than in myofibroblasts (see example 8), but still a 4-foldreduction in mRNA levels can be measured when these cells are culturedin minoxidil containing medium. Minoxidil is thus an example of aninhibitor of PLOD2B mRNA expression and can be used to reduce thecross-links derived from the hydroxyallysine pathway. Lysyl oxidaselevels were not affected by the minoxidil treatment.

Example 8

Inhibition of Telopeptide Lysyl Hydroxylase Using AntisenseOligonucleotides to Decrease Lysyl Hydroxylation Levels in Telopeptides

The expression of TLH can be downregulated at the post-transcriptionallevel by degrading the PLOD2 mRNA using antisense oligonucleotides(AONs). We designed 10 phosphorothioated AONs and tested in vitro theirpotential for duplex formation with the PLOD2 mRNA and subsequentdegradation of the mRNA by RNase H. Non-denatured RNA from 1×10⁴myofibroblasts was incubated for 4 h with 8 μM AON at 37° C. in 15 mMTris-HCI, 2 mM MgCl₂, 50 mM KCI pH 8.0 in a final volume of 25 μl.Degradation of the duplexed mRNA was performed by adding 1 μd 10 mM DTTand 2 u RNase H and incubating the mixture for an additional 20 min at37° C. The remaining RNA was reverse transcribed and subjected to PCRwith the primers: hPLOD2bRTF (5′ TTAAAGGAAAGACACTCCGATCAGAGATGA 3′) (SEQID NO:44) and hPLOD2aRTR4 (5′ TAGCCTTCCAAATTCATGTCTATTAGAAATGTA 3′) (SEQID NO: 45), which have been chosen such that PLOD2a and PLOD2b cDNAamplification can be distinguished in a single reaction. Two AONs out often were able to decrease the amount of PLOD2 mRNA to an undetectablelevel. One recognizes both PLOD2a and PLOD2b mRNA and has the followingsequence: 5′ CCCATATTCGGCCCTC 3′ (SEQ ID NO: 46) (-11-5 nt in the PLOD2cDNA sequence) covering the start codon. The second AON with thesequence 5′ TTCCCTTTGTAAAGT 3′ (SEQ ID NO: 47) (1500-1514 nt in thePLOD2b cDNA sequence) is specific for PLOD2b mRNA and recognizes theextra exon in the PLOD2b sequence. These two AONs are promising fortreating for instance myofibroblasts in order to decrease their PLOD2mRNA levels and as a consequence the amount of HP and LP crosslinks inthe extracellular matrix formed by these cells.

Example 9

Real-Time PCR to Measure PLOD2 mRNA Levels

RNA, obtained from cultured human skin fibroblasts and cultured humanmyofibroblast, was isolated using the RNeasy kit (Qiagen). To remove anygenomic DNA in the RNA sample, a Dnase treatment was carried out, usingRQ1 Rnase-free Dnase (Promega). RNA was then reverse transcripted intocDNA and subjected to real time PCR amplification.

Real time PCR amplification of PLOD2 and P2-microglobulin was performed,using specific primers (PLOD2 forward primer: 5′TTAAAGGAAAGACACTCCGATCAGAGATGA 3′ (SEQ ID NO:48) PLOD2 reverse primer:5′ AATGTTTCCGGAGTAGGGGAGTCTTTTT 3′ (SEQ ID NO:49) β2-microglobulinforward primer: 5′ TCTTGTACTACACTGAATTCACCCCCACTGA 3 (SEQ ID NO:50);β32-microglobulin reverse primer 5′ ATCCAAATGCGGCATCTTCAAACCTC 3′) (SEQIID NO:51) and specific molecular beacons (PLOD2: 5′FAM-cgtgcgCGTGATAAACTGGATCCTGATATGGCTCTT (SEQ ID NO:52) cgcacg-DABCYL3′; P2-microglobulin: 5′HEX-cgtgcCCTGCCGTGTGAACCATGTGACTTTG (SEQ IDNO:53) gcacg-DABCYL 3′). PLOD2 was amplified in a multiplex PCR togetherwith β2-microglobulin in a total reaction volume of 25 μl, containing 1×PCR buffer (Applied Biosystems), 0.4 mM of each dNTP, 3.5 mM Mg²⁺, 250nM of each target primer, 100 nM of each primer for μ2microglobulin and1 unit Amplitaq Gold polymerase (Applied Biosystems). PCR was performedin a ABI PRISM® 7700 Sequence Detection System and consisted of a 5minute interval at 95° C., followed by 40 cycles of 95° C. for 30seconds, 56° C. for 40 seconds and 72° C. for 30 seconds. Data wasanalysed using sequence detector V1.7 software.

FIG. 5 shows that myofibroblast-like cells show in mean a 40-foldincrease of PLOD2 mRNA levels compared to fibroblasts. Myofibroblastsplay a key role in fibrotic processes [C. Badid et al., 2000, Histol.Histopathol., 15: 269-280]. The data indicate that telopeptide lysylhydroxylase is highly upregulated in fibrotic tissues. This is furthercorroborated by our observation, that collagen from skin show very lowlevels of hydroxyallysine cross-links in collagen (0.02 HP residues pertriple helix), whereas collagen laid down in tissues containingmyofibroblasts show high levels of hydroxyallysine cross-links (0.45 HPresidues per triple helix).

As hydroxylation of the telopeptide lysine is controlled by telopeptidelysyl hydroxylase, and as the collagen network containinghydroxyallysine cross-links is more resistant towards proteinases, it isclear that telopeptide lysyl hydroxylase is a key enzyme in fibrosis.The understanding that PLOD2 encodes telopeptide lysyl hydroxylaseprovides the skilled artisan with the necessary information formonitoring the onset and/or progression of fibrotic processes bymeasuring mRNA levels of PLOD2 and/or protein levels of telopeptidelysyl hydroxylase and/or activity levels of telopeptide lysylhydroxylase.

Example 10

High Through-Put Assay

A peptide containing a hydroxylatable lysine residue, such asbiotin-Q-L-S-Y-G-Y-D-E-K-S-T-G-G-I-S-V-P, is dissolved at aconcentration of 1 nmol per 0.1 ml PBS. This was added to a mixture of0.05 ml bovine serum albumin (5 mg albumin Sigma A-7888/ml PBS), 0.05 mlcatalase (3.9 ml PBS+0.1 ml catalase suspesion from Sigma C-100), 0.1 ml1 mM dithiothreitol, 0.05 ml 20 mM ascorbic acid, 0.05 ml 1 mM ferroussulfate, 0.1 ml PBS containing the compound to be tested for itsinhibitory properties towards telopeptide lysyl hydroxylase, 0.1 ml PBScontaining telopeptidase lysyl hydroxylase activity and 0.05 mla-ketoglutarate. The mixture is incubated for 3 hours at 30° C. Analiquot of the mixture (100 μl) is allowed to bind to the streptavidincoated on 96 wells plate (Pierce) at room temperature for 15 min. Thenon-bonded fractions were washed away three times with wash buffer (5%Tween-20 in PBS). The bonded peptides are allowed to react with 100 plof 0.36 gg/ml NalO₄ in 0.025 M phosphate pH 7.0 for 10 min. Anadditional 3 washing steps are carried out before adding 100 μl of 3.1μglml Texas Red hydrazide in 0.1 M sodium acetate/acetonitril (1:2) pH4.5. The solution is gently shaken for 2 h at room temperature. After anine-fold wash step with wash buffer, fluorescence is measured (e.g.with a Cytofluor) at an excitation and emission wave length of 580 nmand 605 nm, respectively. Inhibition of the activity of telopeptidelysyl hydroxylase by the compound in question results in a decrease inthe amount of fluorescence, as lysine cannot be converted into analdehyde in the protocol described above.

Various other hydrazides can be used, such as Lucifer yellow, BODIPYL orCascade Blue. Instead of biotin, a StrepFlag sequence can be used forbinding to the streptavidin. Alternative, other chemistry formats can bechosen, such as a His-tagged peptide in combination with a Ni², carrier,or a SAMA peptide in combination with maleimide-coated plates.

1. A method for obtaining a collagenous matrix which comprisescross-linked collagen molecules, wherein the resistance of saidcollagenous matrix against proteolytic degradation is controlled bycontrolling the ratio of hydroxyallysine cross-links to allysinecross-links in the collagenous matrix.
 2. The method of claim 1 whereinthe ratio of hydroxyallysine cross-links to allysine cross-links in thecollagenous matrix is controlled by controlling the lysyl hydroxylationlevel of the collagen telopeptides.
 3. The method of claim 2 wherein thelysyl hydroxylation level of the collagen telopeptides is controlled bycontrolling the level of telopeptide lysyl hydroxylase activity.
 4. Themethod of claim 3 wherein the level of telopeptide lysyl hydroxylaseactivity is controlled by controlling the expression of a PLOD2 gene orby controlling the telopeptide lysyl hydroxylase activity of a PLOD2expression product.
 5. The method of claim 1 comprising obtainingcollagen from tissues which show an increased ratio of hydroxyallysinecross-links to allysine cross-links and using said collagen to prepare acollagenous matrix with an increased resistance against proteolyticdegradation.
 6. The method of claim 1 comprising obtaining collagen fromtissues which predominantly show allysine cross-links and using saidcollagen for preparing a collagenous matrix, wherein a collagenousmatrix with an increased resistance against proteolytic degradation isobtained by admixing collagen obtained from tissues which show anincreased ratio of hydroxyallysine cross-links to allysine cross-links.7. The method of claim 1 comprising culturing cells producing collagenwith telopeptides having an increased ratio of hydroxylysine to lysineresidues and using the collagen produced for preparing a collagenousmatrix having an increased resistance against proteolytic degradationdue to an increased ratio of hydroxyallysine cross-links to allysinecross-links.
 8. The method of claim 7 wherein said collagen-producingcells comprise a recombinant, constitutively expressed PLOD2 gene. 9.The method of claim 7 wherein said collagen-producing cells are culturedin the presence of a composition which stimulates the expression of aPLOD2 gene.
 10. The method of claim 1 comprising obtaining collagen fromtissues which show a decreased ratio of hydroxyallysine cross-links toallysine cross-links and using said collagen to prepare a collagenousmatrix with a decreased resistance against proteolytic degradation. 11.The method of claim 1 comprising obtaining collagen from tissues whichpredominantly show hydroxyallysine cross-links and using said collagenfor preparing a collagenous matrix, wherein a collagenous matrix with adecreased resistance against proteolytic degradation is obtained byadmixing collagen obtained from tissues which show a decreased ratio ofhydroxyallysine cross-links to allysine cross-links.
 12. The method ofclaim 1 comprising culturing cells producing collagen with telopeptideshaving a decreased ratio of hydroxylysine to lysine residues and usingthe collagen produced for preparing a collagenous matrix having adecreased resistance against proteolytic degradation due to a decreasedratio of hydroxyallysine cross-links to allysine cross-links.
 13. Themethod of claim 12 wherein said collagen-producing cells are cultured inthe presence of a composition which inhibits the activity or productionof PLOD2-encoded telopeptide lysyl hydroxylase.
 14. The method of claim13 wherein said composition does not affect the level of lysyl oxidase.15. The method of claim 1 comprising treating a fibrotic condition in amammal by administering to said mammal an effective amount of a compoundor composition which reduces the lysyl hydroxylation level of collagentelopeptides and thereby results in a collagenous matrix having adecreased ratio of hydroxyallysine cross-links to allysine crosslinks.16. The method of claim 15 comprising administration of an effectiveamount of a compound or composition that inhibits the activity orproduction of telopeptide lysyl hydroxylase encoded by a PLOD2 gene butnot the activity or production of lysyl oxidase.
 17. The method of claim16 wherein said compound or composition comprises a compound that bindsto the subsite or subsites of the active site of said telopeptide lysylhydroxylase destined for binding of the co-substrate 2-oxoglutarate,thereby replacing the 2-oxoglutarate.
 18. The method of claim 16 whereinsaid compound or composition comprises a compound that chelates the Fe²⁺bound in the active site of said telopeptide lysyl hydroxylase, therebyinhibiting the oxygen atom acceptor function of said Fe 2+ and/orinhibiting of said Fe²⁺ to 2-oxoglutarate.
 19. The method of claim 16wherein said compound or composition comprises an anthracycline or acoumalic acid analogue that syncatalytically inactivates saidtelopeptide lysyl hydroxylase.
 20. The method of claim 16 wherein saidcompound or composition comprises a peptide or peptidomimetic containinga non-physiological lysine derivative in a hydroxylatable position whichsyncatalytically nactivates said telopeptide lysyl hydroxylas
 21. Themethod of claim 16 wherein said compound or composition comprises ahydroxylatable peptide or peptidomimetic that competes with the naturalsubstrate for the active site of said telopeptide lysyl hydroxylase. 22.The method of claim 16 wherein said compound or composition comprises aPon-hydroxylatable peptide or peptidomimetic that competes with thenatural substrate for the active site of said telopeptide lysylhydroxylase.
 23. The method of claim 16 wherein said compound orcomposition comprises a compound that is a non-reducing ascorbate thatbinds to the active site of said telopeptide lysyl hydroxylase, therebyreplacing ascorbate.
 24. The method of claim 16 wherein said compound orcomposition comprises a peptide or peptidomimetic with anon-hydroxylatable sequence capable of enhancing the uncoupled reactionof said telopeptide lysyl hydroxylase, resulting in an increased levelof the inactive self-oxidized form of said telopeptide lysylhydroxylase.
 25. The method of claim 16 wherein said compound orcomposition comprises a compound found by means of screening compoundlibraries (combinatorial chemistry).
 26. The method of claim 16 whereinsaid compound or composition comprises an antibody or an aptamer thatselectively inhibits the activity of telopeptide lysyl hydroxylase. 27.The method of claim 26 wherein said antibody or aptamer reacts with ornear the active site of said telopeptide lysyl hydroxylase.
 28. Themethod of claim 26 wherein said antibody or aptamer reacts with thetelopeptides, thereby inhibiting the reaction of said enzyme by means ofsteric hindrance.
 29. The method of claim 16 wherein said compound orcomposition contains a compound that selectively inhibits thetranscription of a telopeptide lysyl hydroxylase gene.
 30. The method ofclaim 29 wherein said compound is minoxidil or a minoxidil analogue. 31.The method of claim 16 wherein said compound or composition contains anantisense RNA in order to inhibit the translation of mRNA derived from atelopeptide lysyl hydroxylase gene.
 32. The method of claim 16 whereinsaid compound or composition contains a recombinant gene encoding amutated telopeptide lysyl hydroxylase that shows no activity towardstelopeptides but that is competitive to endogenous telopeptide lysylhydroxylase with respect to its natural substrate (collagentelopeptides).
 33. The method of claim 16 wherein said compound orcomposition is a hydroxylatable peptide or a sequence encoding such apeptide that is competitive to collagen telopeptides with respect to thereaction that is normally catalyzed by telopeptide lysyl hydroxylase.34. The method of claim 15 wherein said mammal is a human being. 35.(canceled)
 36. (canceled)
 37. (canceled)
 38. (canceled)
 39. (canceled)40. (canceled)
 41. (canceled)
 42. (canceled)